S.Biomedics owns two platform technologies with excellent technical power and expandability. We are currently developing cell therapy products that overcome the limitations of existing cell therapy products by using the two source technologies. We endeavor to enhance the technology and company value by expanding the therapy product area for various indications.
“Functionally Enhanced Cell Spheroid”
FECSTM technology is a 3D cell spheroid (3D spherical cell cluster) formation technology for cell function enhancement. An excellent effect is expected by enhancing cell functions and creating an environment similar to that of the body. FECSTM has a great potential for the application to the development of cell therapy products, because that is safe to the human body, and its production process is stable and is applicable to various types of cells.
“Targeted Embryonic Stem Cell Differentiation”
As a standardized and efficient neural precursor cell differentiation technology, TED technology can be applied to all pluripotent stem cell lines. By overcoming the different differentiation tendencies of each pluripotent stem cell line, it can induce efficient differentiation of all pluripotent stem cell lines into neural precursor cells. The neural precursor cells obtained as a result become the source of treatment for intractable nervous diseases.
We use 2 core platform technologies to expand to 8 R&D pipelines.